CN Patent

CN108699061A — 用于治疗血液恶性肿瘤、炎症和自身免疫性疾病的氘代化合物

Assigned to Niufumu Pharmaceutical Co Ltd · Expires 2018-10-23 · 8y expired

What this patent protects

本发明提供对于治疗各种血液恶性肿瘤及炎症和自身免疫性疾病或其相关疾病或病症有用的新型化学化合物，以及其药物组合物及制备方法和用途。

USPTO Abstract

本发明提供对于治疗各种血液恶性肿瘤及炎症和自身免疫性疾病或其相关疾病或病症有用的新型化学化合物，以及其药物组合物及制备方法和用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN108699061A
Jurisdiction
CN
Classification
—
Expires
2018-10-23
Drug substance claim
No
Drug product claim
No
Assignee
Niufumu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.